215 related articles for article (PubMed ID: 34870237)
21. Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities.
Vasaikar S; Huang C; Wang X; Petyuk VA; Savage SR; Wen B; Dou Y; Zhang Y; Shi Z; Arshad OA; Gritsenko MA; Zimmerman LJ; McDermott JE; Clauss TR; Moore RJ; Zhao R; Monroe ME; Wang YT; Chambers MC; Slebos RJC; Lau KS; Mo Q; Ding L; Ellis M; Thiagarajan M; Kinsinger CR; Rodriguez H; Smith RD; Rodland KD; Liebler DC; Liu T; Zhang B;
Cell; 2019 May; 177(4):1035-1049.e19. PubMed ID: 31031003
[TBL] [Abstract][Full Text] [Related]
22. Proteogenomic landscape of squamous cell lung cancer.
Stewart PA; Welsh EA; Slebos RJC; Fang B; Izumi V; Chambers M; Zhang G; Cen L; Pettersson F; Zhang Y; Chen Z; Cheng CH; Thapa R; Thompson Z; Fellows KM; Francis JM; Saller JJ; Mesa T; Zhang C; Yoder S; DeNicola GM; Beg AA; Boyle TA; Teer JK; Ann Chen Y; Koomen JM; Eschrich SA; Haura EB
Nat Commun; 2019 Aug; 10(1):3578. PubMed ID: 31395880
[TBL] [Abstract][Full Text] [Related]
23. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
24. Proteogenomic Platform for Identification of Tumor Specific Antigens.
Faktor J; Hernychová L; Vojtěšek B; Hupp T
Klin Onkol; 2018; 31(Suppl 2):102-107. PubMed ID: 31023032
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study.
Bai X; Wu DH; Ma SC; Wang J; Tang XR; Kang S; Fu QJ; Cao CH; Luo HS; Chen YH; Zhu HB; Yan HH; Wu YL; Dong ZY
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606052
[TBL] [Abstract][Full Text] [Related]
26. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
27. Cancer neoantigen prioritization through sensitive and reliable proteogenomics analysis.
Wen B; Li K; Zhang Y; Zhang B
Nat Commun; 2020 Apr; 11(1):1759. PubMed ID: 32273506
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.
Zhang H; Liu M; Du G; Yu B; Ma X; Gui Y; Cao L; Li X; Tan B
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1597-1612. PubMed ID: 35296921
[TBL] [Abstract][Full Text] [Related]
29. Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways.
Zhang Y; Chen F; Chandrashekar DS; Varambally S; Creighton CJ
Nat Commun; 2022 May; 13(1):2669. PubMed ID: 35562349
[TBL] [Abstract][Full Text] [Related]
30. Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S; Du W; Sun Q; Zhao X; Qin B; Shi D; Wan C; Wu Z
Cancer Med; 2021 Oct; 10(20):7360-7372. PubMed ID: 34599863
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
[TBL] [Abstract][Full Text] [Related]
32. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
33. Lung Cancer Proteogenomics: Shaping the Future of Clinical Investigation.
Vavilis T; Petre ML; Vatsellas G; Ainatzoglou A; Stamoula E; Sachinidis A; Lamprinou M; Dardalas I; Vamvakaris IN; Gkiozos I; Syrigos KN; Anagnostopoulos AK
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539567
[TBL] [Abstract][Full Text] [Related]
34. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
Faruki H; Mayhew GM; Serody JS; Hayes DN; Perou CM; Lai-Goldman M
J Thorac Oncol; 2017 Jun; 12(6):943-953. PubMed ID: 28341226
[TBL] [Abstract][Full Text] [Related]
35. Identification of prognostic biomarkers for major subtypes of non-small-cell lung cancer using genomic and clinical data.
Lathwal A; Kumar R; Arora C; Raghava GPS
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2743-2752. PubMed ID: 32661603
[TBL] [Abstract][Full Text] [Related]
36. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
Datar I; Sanmamed MF; Wang J; Henick BS; Choi J; Badri T; Dong W; Mani N; Toki M; Mejías LD; Lozano MD; Perez-Gracia JL; Velcheti V; Hellmann MD; Gainor JF; McEachern K; Jenkins D; Syrigos K; Politi K; Gettinger S; Rimm DL; Herbst RS; Melero I; Chen L; Schalper KA
Clin Cancer Res; 2019 Aug; 25(15):4663-4673. PubMed ID: 31053602
[TBL] [Abstract][Full Text] [Related]
37. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
[TBL] [Abstract][Full Text] [Related]
38. Identification of logic relationships between genes and subtypes of non-small cell lung cancer.
Su Y; Pan L
PLoS One; 2014; 9(4):e94644. PubMed ID: 24743794
[TBL] [Abstract][Full Text] [Related]
39. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
40. Variant peptide detection utilizing mass spectrometry: laying the foundations for proteogenomic identification and validation.
Dimitrakopoulos L; Prassas I; Berns EMJJ; Foekens JA; Diamandis EP; Charames GS
Clin Chem Lab Med; 2017 Aug; 55(9):1291-1304. PubMed ID: 28157690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
